Floatz Rating
C39/100
Confidence
Indicative
Sponsor
Wake Forest University Health Sciences
Modality
mixture
Development Phase
Early Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
24Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04734106CT.gov Safety and Efficacy of Aloe Vera in the Management of the Symptoms of Interstitial Cystitis | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Interstitial Cystitis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Aloe Vera Polysaccharide Extract (this asset) | Wake Forest University Health Sciences | Early P1 | C · 39 |
| Cyclic Microgestin 1/20 | Endeavor Health | P4 | BB |
| Continuous Microgestin 1/20 | Endeavor Health | P4 | BB |
| Doxycycline | Insel Gruppe AG, University Hospital Bern | P4 | B |
| Gabapentin | Jocelyn Fitzgerald | P3 | B |
| Gralise | Shirley Ryan AbilityLab | P4 | B |
| Amitriptyline | Jocelyn Fitzgerald | P3 | B |
| Methenamine | Jocelyn Fitzgerald | P3 | B |
| Rosiptor | Aquinox Pharmaceuticals (Canada) Inc. | P3 | B |
+16 more in the Interstitial Cystitis cohort
Other indications for Aloe Vera Polysaccharide Extract
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Radiodermatitis | — | N/A | D · 30 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Aloe Vera Polysaccharide Extract in Interstitial Cystitis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/aloe-vera-polysaccharide-extract-interstitial-cystitis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →